Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIT012
- Development stage
- Preclinical
- Lead developer
- EpimAb Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
FIT012 is a preclinical oncology bispecific antibody generated using EpimAb Biotherapeutics’ proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform and licensed to Zhejiang Teruisi Biopharmaceutical for development and commercialization in mainland China.[3][5][7] The program, also known as TRS008, targets two undisclosed receptors on cancer cells and is intended to leverage dual-receptor blockade for synergistic antitumor activity, consistent with other FIT-Ig bispecifics such as EMB01 that simultaneously engage EGFR and cMET.[3] FIT012 has completed extensive preclinical validation and remains in early development without publicly disclosed clinical trials or specific tumor indications beyond its positioning as a broad oncology candidate.[3][5][7]
- Other names
- FIT012FIT-012FIT 012
Beyond the preview
Go deeper on FIT012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIT012.